CTOs on the Move

Pacific Biosciences

www.pacb.com

 
Pacific Biosciences is developing an environment in which scientists can seamlessly integrate multiple data types from multiple sources and deploy advanced bioinformatics methods to elucidate the complexity of living systems. Therefore, we are committed
  • Number of Employees: 250-1000
  • Annual Revenue: $500M-1 Billion
  • www.pacb.com
  • 1380 Willow Rd
    Menlo Park, CA USA 94025
  • Phone: 650.521.8000

Executives

Name Title Contact Details
Tobias Mann
Vice President of Software Engineering Profile

Funding

Pacific Biosciences raised $900M on 02/10/2021

Similar Companies

ARIAD Pharmaceuticals, Inc.

ARIAD is a pharmaceutical company whose vision is to transform the lives of cancer patients with breakthrough medicines.

Spectrex Corp

Spectrex Corp is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Inspirion Biosciences

Inspirion Biosciences protects the advancement of science, the safety and security of researchers, and the health of surrounding communities through integrated solutions in risk strategy. Learn more here.

Optherion Inc

Optherion Inc is a New Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genfit

GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments. GENFIT is a leader in the field of nuclear receptor-based drug discovery with a rich history and strong scientific heritage spanning almost two decades. Its most advanced drug candidate, elafibranor, is currently evaluated in pivotal Phase 3 clinical trial (“RESOLVE-IT”) as a potential treatment for nonalcoholic steatohepatitis, or NASH. NASH is considered by regulatory authorities as a medical emergency because of its potentially severe consequences, although often asymptomatic until late stages, and because its prevalence is on the rise. Elafibranor has also obtained positive preliminary results in a Phase 2 clinical trial in primary biliary cholangitis (PBC), a severe chronic liver disease. As part of GENFIT’s comprehensive approach to clinical management of NASH patients, the Company is also developing a new, non-invasive and easy-to-access blood-based in vitro diagnostic, or IVD, test to identify patients with NASH who may be appropriate candidates for drug therapy. With facilities in Lille and Paris, France, and Cambridge, MA, USA, the Company has approximately 170 employees. GENFIT is a public company listed on the Nasdaq Global Select Market and in compartment B of Euronext’s regulated market in Paris.